Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$3.05 - $4.34 $482,574 - $686,679
-158,221 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$2.82 - $4.67 $446,183 - $738,892
158,221 New
158,221 $492,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.